{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:54:38Z","timestamp":1793390078095,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["# 2021024"],"award-info":[{"award-number":["# 2021024"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>TNF-\u03b1 inhibitors (TNFis) are effective biologic drugs for rheumatoid arthritis (RA), but their comparative efficacy is unclear due to limited direct comparisons. The objective of this work was to compare the efficacy of infliximab (INX), certolizumab pegol (CZP), etanercept (ETN), golimumab (GOM) and adalimumab (ADM) in achieving remission at 3\u2009months in bio-na\u00efve RA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the NOR-DMARD study of adult RA patients in Norway starting a TNFi as their first biologic treatment, we employed a target trial emulation approach. TNFi selection is mainly determined by drug prices in annual national tenders, allowing us to use drug cost as an instrumental variable (IV). Applying a novel IV method, causal effects were estimated with remission at 3\u2009months as the end point. Results were compared with standard regression analysis adjusted for baseline variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The IV analysis suggested potential differences in efficacy among TNFis, with INX showing higher remission rates compared with CZP, and ETN performing better than GOM. However, confidence intervals were wide, and many comparisons were not statistically significant. Sensitivity analyses confirmed the overall direction of results. Regression analysis adjusting for observed confounders showed no substantial differences, underscoring the importance of addressing unobserved confounding effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This hypothesis-generating study provides evidence that TNFis may not be equally effective. The uncertainty in the estimates highlights the need for a pragmatic randomized controlled trial to validate the findings. With decreasing costs of TNFis, such studies are increasingly feasible and critical to guide clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag007","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:29:02Z","timestamp":1768415342000},"source":"Crossref","is-referenced-by-count":1,"title":["A head-to-head comparison of TNF-\u03b1 inhibitors as the first biologic treatment of rheumatoid arthritis"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-6203","authenticated-orcid":false,"given":"Amir Aamodt","family":"Kazemi","sequence":"first","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo , Oslo,","place":["Norway"]},{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]},{"name":"Department of Research Support for Clinical Trials, Oslo University Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik Klami","family":"Kristianslund","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Minde","family":"Fagerli","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sella Aarrestad","family":"Provan","sequence":"additional","affiliation":[{"name":"Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Christoffer","family":"Olsen","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics and Epidemiology, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo , Oslo,","place":["Norway"]},{"name":"Department of Research Support for Clinical Trials, Oslo University Hospital , Oslo,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2026101901164418600_keag007-B1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2026101901164418600_keag007-B2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological dmards: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026101901164418600_keag007-B3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40259-022-00559-1","article-title":"Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine","volume":"36","author":"Gehin","year":"2022","journal-title":"BioDrugs"},{"key":"2026101901164418600_keag007-B4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrrheum.2013.134","article-title":"Biologic agents in rheumatology: unmet issues after 200 trials and 200 billion sales","volume":"9","author":"Ioannidis","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2026101901164418600_keag007-B5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the eular recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026101901164418600_keag007-B6","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised exxelerate study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2026101901164418600_keag007-B7","doi-asserted-by":"crossref","first-page":"152249","DOI":"10.1016\/j.semarthrit.2023.152249","article-title":"Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: a systematic review","volume":"62","author":"Sparks","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"2026101901164418600_keag007-B8","first-page":"18","article-title":"Drug procurement cooperation (lis)-Norwegian tender system to reduce cost of expensive medicines","author":"Mielnik","year":"2014","journal-title":"J Health Policy Outcomes Res"},{"key":"2026101901164418600_keag007-B9","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1177\/09622802241281960","article-title":"Instrumental variable analysis with categorical treatment","volume":"33","author":"Kazemi","year":"2024","journal-title":"Stat Methods Med Res"},{"key":"2026101901164418600_keag007-B10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/sim.4780100707","article-title":"Estimating standardized parameters from generalized linear models","volume":"10","author":"Greenland","year":"1991","journal-title":"Stat Med"},{"key":"2026101901164418600_keag007-B11","first-page":"0","article-title":"Standardization as a tool for causal inference in medical research","volume":"19","author":"Gharibzadeh","year":"2016","journal-title":"Arch Iran Med"},{"key":"2026101901164418600_keag007-B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026101901164418600_keag007-B13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1257\/aer.91.2.107","article-title":"Policy-relevant treatment effects","volume":"91","author":"Heckman","year":"2001","journal-title":"Am Econ Rev"},{"key":"2026101901164418600_keag007-B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"2026101901164418600_keag007-B15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mpr.329","article-title":"Multiple imputation by chained equations: what is it and how does it work?","volume":"20","author":"Azur","year":"2011","journal-title":"Int J Methods Psychiatr Res"},{"key":"2026101901164418600_keag007-B16","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"Schomaker","year":"2018","journal-title":"Stat Med"},{"key":"2026101901164418600_keag007-B17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.joca.2012.03.005","article-title":"Consequences of handling missing data for treatment response in osteoarthritis: a simulation study","volume":"20","author":"Olsen","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"2026101901164418600_keag007-B18","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with covid-19: final results of the who solidarity randomised trial and updated meta-analyses","volume":"399","author":"Pan","year":"2022","journal-title":"Lancet"},{"key":"2026101901164418600_keag007-B19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe2025674","volume-title":"The RECOVERY platform","author":"Normand","year":"2021"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag007\/66413723\/keag007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag007\/66413723\/keag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag007\/66413723\/keag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:16:48Z","timestamp":1792387008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag007\/8425605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag007","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,14]]},"article-number":"keag007"}}